 LONDON, Nov. 03, 2022 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the American Society of Hematology ASH Annual Meeting, to be held December 10-13, 2022. 